BioMarin: 'Strong Buy' On VOXZOGO Expansion And Amicus Acquisition

Verdict

Headline leans bullish. We score BMRN +1.00.

Score confirms the headline.

Headline says

Leans bullish

From its wording — no explicit rating

=

Expected · BMRN

+1.00strongly bullish

−1 bearish0bullish +1

More positive than 99% of ticker scores this week

Actual

• m and a
• biotech
• pharmaceuticals
• BMRN
• acquisition
• clinical trials
• drug pipeline
• fda label expansion
• rare disease
• revenue guidance

Search tags